Patents by Inventor David D. Mundschenk
David D. Mundschenk has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20140256762Abstract: The present invention describes a method of treating individuals suffering from microbial infections, including a viral infection such as Dengue Fever, using an improved Artemisinin Combination Therapy (ACT), known as Tri-ACT. The improved ACT therapy includes administering a combination of three drugs. In one embodiment of the present invention, the method includes administering to an individual a first composition comprising a therapeutically effective amount of an artemether spray sublingually. The individual is then administered a second composition, a therapeutically effective amount of artesunate. A third composition, an effective amount of berberine, or its pharmaceutically acceptable derivatives or salts is then administered to the individual.Type: ApplicationFiled: March 7, 2014Publication date: September 11, 2014Inventors: Robert Lewis Steele, Anthony Fedele Musso, David D. Mundschenk, Russell Van de Casteele
-
Publication number: 20140256761Abstract: The present invention describes a method of treating individuals suffering from microbial infections, including a parasitic disease such as malaria, by using an improved Artemisinin Combination Therapy (ACT), known as ActRx Tri-ACT Plus. The improved ACT therapy includes administering a combination of four drugs. In one embodiment of the present invention, the method includes administering to an individual a first composition comprising a therapeutically effective amount of an artemether spray sublingually. The individual is then administered a second composition, a therapeutically effective amount of artesunate. A third composition, an effective amount of berberine, or its pharmaceutically acceptable derivatives or salts is administered to the individual. A fourth composition, an effective amount of primaquine, or its pharmaceutically acceptable derivatives or salts is administered to the individual.Type: ApplicationFiled: March 7, 2014Publication date: September 11, 2014Inventors: Robert Lewis Steele, Anthony Fedele Musso, David D. Mundschenk, Russell Van de Casteele
-
Publication number: 20080248992Abstract: A composition and method for preventing HIV infection of mammalian cells. One aspect of the invention relates to an anti-immunodeficiency virus immunokine capable of binding to a cellular protein in a manner that prevents HIV infection of that cell. The compositions can include either an active bioactive polypeptide, such as native cobratoxin, and/or an inactivated bioactive polypeptide, such as cobratoxin in which one or more of the native disulfide bridges have been prevented from forming. The term “immunokine” is used to refer to an inactivated bioactive polypeptide, whether inactivated by chemical, genetic, and/or synthetic means as described herein, with the proviso that a corresponding active bioactive polypeptides can be included where applicable (e.g., for in vitro use).Type: ApplicationFiled: May 9, 2006Publication date: October 9, 2008Inventors: David D. Mundschenk, Paul F. Reid
-
Patent number: 7060253Abstract: A system for delivering a chemical agent in the form of a spray or foam, which in a preferred embodiment involves the use of an aerosol dispenser to deliver a formulation containing both an anionic surface active agent such as sodium lauryl sulfate as a foaming agent and a chemical agent such as either hydrogen peroxide as a disinfecting chemical agent or natural sea water.Type: GrantFiled: September 20, 1996Date of Patent: June 13, 2006Inventor: David D. Mundschenk
-
Publication number: 20040197270Abstract: A system for delivering a chemical agent in the form of a foam, which in its preferred embodiment involves the use of an aerosol dispenser to deliver a formulation containing both an anionic surface active agent such as sodium lauryl sulfate as a delivery agent and a chemical agent such as either hydrogen peroxide as a disinfecting chemical agent or natural sea water.Type: ApplicationFiled: April 1, 2003Publication date: October 7, 2004Inventor: David D. Mundschenk
-
Patent number: 6670148Abstract: A method of preparing a bioactive polypeptide in a stable, inactivated form, the method comprising the step of treating the polypeptide with ozonated water in order to oxidize and/or stabilize the cysteine residues, and in turn, prevent the formation of disulfide bridges necessary for bioactivity. The method can involve the use of ozonated water to both oxidize the disulfide bridges in a bioactive polypeptide, and to then stabilize the resultant cysteine residues. Optionally, and preferably, the method can involve the use of ozonated water to stabilize the cysteine residues, and thereby prevent the formation of disulfide bridges, in a polypeptide produced by recombinant means in a manner that allows the polypeptide to be recovered with the disulfide bridges unformed.Type: GrantFiled: August 5, 1999Date of Patent: December 30, 2003Assignee: BioTherapeutics, Inc.Inventors: David D. Mundschenk, Leonard A. Smith
-
Publication number: 20030215437Abstract: A method of preparing a bioactive polypeptide in a stable, inactivated form, the method comprising the step of treating the polypeptide with ozonated water in order to oxidize and/or stabilize the cysteine residues, and in turn, prevent the formation of disulfide bridges necessary for bioactivity. The method can involve the use of ozonated water to both oxidize the disulfide bridges in a bioactive polypeptide, and to then stabilize the resultant cysteine residues. Optionally, and preferably, the method can involve the use of ozonated water to stabilize the cysteine residues, and thereby prevent the formation of disulfide bridges, in a polypeptide produced by recombinant means in a manner that allows the polypeptide to be recovered with the disulfide bridges unformed.Type: ApplicationFiled: November 7, 2002Publication date: November 20, 2003Inventors: David D. Mundschenk, Leonard A. Smith
-
Publication number: 20030211465Abstract: A composition and method for preventing HIV infection of mammalian cells. One aspect of the invention relates to an anti-immunodeficiency virus immunokine capable of binding to a cellular protein in a manner that prevents HIV infection of that cell. The compositions can include either an active bioactive polypeptide, such as native cobratoxin, and/or an inactivated bioactive polypeptide, such as cobratoxin in which one or more of the native disulfide bridges have been prevented from forming. The term “immunokine” is used to refer to an inactivated bioactive polypeptide, whether inactivated by chemical, genetic, and/or synthetic means as described herein, with the proviso that a corresponding active bioactive polypeptides can be included where applicable (e.g., for in vitro use).Type: ApplicationFiled: November 12, 2002Publication date: November 13, 2003Inventors: David D. Mundschenk, Paul F. Reid
-
Publication number: 20020068317Abstract: A method of preparing a bioactive polypeptide in a stable, inactivated form, the method comprising the step of treating the polypeptide with ozonated water in order to oxidize and/or stabilize the cysteine residues, and in turn, prevent the formation of disulfide bridges necessary for bioactivity. The method can involve the use of ozonated water to both oxidize the disulfide bridges in a bioactive polypeptide, and to then stabilize the resultant cysteine residues. Optionally, and preferably, the method can involve the use of ozonated water to stabilize the cysteine residues, and thereby prevent the formation of disulfide bridges, in a polypeptide produced by recombinant means in a manner that allows the polypeptide to be recovered with the disulfide bridges unformed.Type: ApplicationFiled: August 5, 1999Publication date: June 6, 2002Inventors: DAVID D. MUNDSCHENK, LEONARD A. SMITH
-
Patent number: 6284012Abstract: Kelp/seaweed extract biocatalyst compositions, methods of making the kelp/seaweed extract biocatalyst compositions and methods of using these biocatalyst compositions are disclosed. The biocatalyst compositions are useful in wastewater treatment, bioremediation and the elimination of grease from grease traps and sewage systems. In addition, the biocatalyst compositions are useful in home, garden and lawn care applications.Type: GrantFiled: November 16, 1998Date of Patent: September 4, 2001Inventors: David D. Mundschenk, Paul Reid
-
Patent number: 5989857Abstract: A method of preparing a bioactive polypeptide in a stable, inactivated form, the method comprising the step of treating the polypeptide with ozonated water in order to oxidize and/or stabilize the cysteine residues, and in turn, prevent the formation of disulfide bridges necessary for bioactivity. The method can involve the use of ozonated water to both oxidize the disulfide bridges in a bioactive polypeptide, and to then stabilize the resultant cysteine residues. Optionally, and preferably, the method can involve the use of ozonated water to stabilize the cysteine residues, and thereby prevent the formation of disulfide bridges, in a polypeptide produced by recombinant means in a manner that allows the polypeptide to be recovered with the disulfide bridges unformed.Type: GrantFiled: August 7, 1997Date of Patent: November 23, 1999Assignee: PhyloMed CorporationInventor: David D. Mundschenk
-
Patent number: 5665332Abstract: A system for delivering a chemical agent in the form of a foam, which in its preferred embodiment involves the use of a propellantless dispenser to deliver a formulation containing both an anionic surface active agent such as sodium lauryl sulfate as a foaming agent and hydrogen peroxide as a disinfecting chemical agent.Type: GrantFiled: March 28, 1994Date of Patent: September 9, 1997Assignee: OralCare Systems, Inc.Inventors: David D. Mundschenk, Albert Saferstein, Gary Gerard Fores
-
Patent number: 5512278Abstract: An ointment base useful for preparing topically applied medicament formulations. The base can be provided in the form of a stable emulsion including paraffin(s), polyol, beeswax, cetostearyl alcohol, a 4-hydroxy benzoic acid lower alkyl ester, a surface active agent and a dispersing agent. The base can be combined with large volumes containing a variety of medicaments to form stable, useful formulations.Type: GrantFiled: January 11, 1994Date of Patent: April 30, 1996Assignee: PhyloMed CorporationInventor: David D. Mundschenk
-
Patent number: 4338564Abstract: A control blood platelet preparation containing a population of platelets of known count range, electronic volume and electronic volume size distribution is used to check the threshold setting calibrations of an electronic particle counter. The control preparation preferably contains blood platelets from whole blood taken from animal species which are non-infectious with respect to human hepatitis, ideally animals of the bovine and parcine species.Type: GrantFiled: November 5, 1980Date of Patent: July 6, 1982Assignee: R & D Systems, Inc.Inventor: David D. Mundschenk
-
Patent number: 4324686Abstract: A control blood platelet preparation containing a population of platelets of known count range, electronic volume and electronic volume size distribution is ued to check the threshold setting calibrations of an electronic particle counter. The control preparation preferably contains blood platelets from whole blood taken from animal species which are non-injectious with respect to human hepatitis, ideally animals of the bovine and porcine species.Type: GrantFiled: June 11, 1979Date of Patent: April 13, 1982Assignee: R & D Systems, Inc.Inventor: David D. Mundschenk